OrphoMed's IBS-D Candidate ORP-101 Receives Fast Track Designation

In June of 2017, OrphoMed announced that they had closed a $39 Million series A round to accelerate development of their lead candidate, ORP-101, IBS-D. On 4/25/18 they announced that the FDA has granted Fast Track designation for the Company's lead candidate ORP-101 for the treatment of irritable bowel syndrome with diarrhea (IBS-D).